Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera

Novo Nordisk has entered a competitive bidding race with Pfizer to acquire U.S. biotech Metsera, intensifying the battle for next-generation obesity drug assets. The move underscores Novo Nordisk’s strategy to protect and extend its dominance in the metabolic-disease market, as competition from multi-agonist drug developers accelerates. Metsera, backed by major venture capital investors, is developing early-stage obesity and metabolic candidates that could complement or challenge current GLP-1 and GIP-based therapies. Novo Nordisk’s entry into the bidding process signals the company’s intent to secure future-proof innovation amid rising pressure from Eli Lilly’s market momentum. Analysts say the acquisition could influence the direction of the obesity-drug landscape in the next decade, as pharma companies race to secure assets that offer greater efficacy, better tolerability and broader metabolic benefits.